April 2, 2022 | Targeted Therapies in Oncology

TRESR Study Identifies Tolerable Dosing Schedule for ATR Inhibitor RP-3500

April 15, 2022

Clinical Articles

RP-3500 dosed at 160-mg dose on a 3 days on/4 days off continuous cycle appears to be the most tolerable for patients with selected ATR-inhibitor-sensitizing DNA damage response alterations, according to the TRESR study.

10 Years in CLL: Top Advances From 2012-2022

April 14, 2022

Clinical Articles

The past decade has seen the FDA approve a handful of new targeted therapies for chronic lymphocytic leukemia that are prompting a move toward chemotherapy-free treatment of the disease.

ctDNA Is Improving Oncology Care and Should Be Part of the Standard of Care

April 14, 2022

Clinical Articles

Many oncologists, including surgeons, medical oncologists, and radiation oncologists, have already started to incorporate ctDNA testing as part of their standard practice to monitor treatment response and aid in the interpretation of equivocal imaging findings and in surveillance for recurrence.

Immunotherapy Hits Its Stride in Esophageal and GEJ Cancers

April 14, 2022

Clinical Articles

The recent, significant advances for immunotherapy in esophageal and gastroesophageal junction cancer are promising, and oncologists hope it is just the beginning of further improvements in patient outcomes.